Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01499563 · ClinicalTrials.gov registry record · Phase 2
Study of a Novel Antipsychotic ITI-007 in Schizophrenia
A Phase 2 study, sponsored by Intra-Cellular Therapies.
- Completed
- Registry status
- Phase 2
- Development phase
- 335
- Enrollment target
NCT01499563 is a Phase 2 study that has completed, run by Intra-Cellular Therapies. The registered enrollment target is 335 participants.
The verdict
NCT01499563, a Phase 2 study, has completed, sponsored by Intra-Cellular Therapies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 335 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether ITI-007 is effective in reducing symptoms associated with schizophrenia in patients who are having an acute worsening of their psychosis. Patients will be randomly assigned to receive one of two doses of ITI-007, placebo, or a positive control. The primary goal will be to assess the effects of ITI-007 on psychosis. The safety of ITI-007 will also be assessed.
Interventions
- DRUG Placebo
- DRUG Risperidone
- DRUG ITI-007
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 335 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01499563
The ClinicalTrials.gov registry entry for NCT01499563 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 335 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intra-Cellular Therapies, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01499563 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01499563 about?
NCT01499563 is a clinical study titled "Study of a Novel Antipsychotic ITI-007 in Schizophrenia". The purpose of this study is to evaluate whether ITI-007 is effective in reducing symptoms associated with schizophrenia in patients who are having an acute worsening of their psychosis. Patients will be randomly assigned to receive one of two doses of ITI-007, placebo, or a positive control. The pr...
What is the current status of trial NCT01499563?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 335 participants. The study started on 2011-12. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01499563?
The interventions under investigation include: Placebo (DRUG), Risperidone (DRUG), ITI-007 (DRUG).
Who is sponsoring clinical trial NCT01499563?
This trial is sponsored by Intra-Cellular Therapies, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.